Last update 22 Dec 2025
Santen Pharmaceutical (China) Co. Ltd.

Santen Pharmaceutical (China) Co. Ltd.

Subsidiary Company|2005|Jiangsu Sheng, China|
www.santen-china.com.cn

Overview

Tags

Eye Diseases
Immune System Diseases
Small molecule drug
Non-degrading molecular glue
Polymer

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases2
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Neoplasms1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Non-degrading molecular glue1
Polymer1
Synthetic peptide1
Polysaccharide1
Top 5 TargetCount
CaN(Calcineurin)1
PTGFR x β-adrenoceptors1

Related

3
Drugs associated with Santen Pharmaceutical (China) Co. Ltd.
Tafluprost/Timolol Maleate
Target
PTGFR x β-adrenoceptors
Mechanism
PTGFR agonists [+1]
Active Org.
Santen Oy [+2]
Originator Org.
Santen SAS [+1]
Active Indication
Glaucoma, Open-Angle [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date20 Sep 2013
Sodium Hyaluronate
Target-
Mechanism-
Active Org.
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd. [+10]
Originator Org.
Seikagaku Corp.Seikagaku Corp.
Active Indication
Keratoplasty rejection [+14]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date29 Nov 1986
Cyclosporine
Target
CaN
Mechanism
CaN inhibitors
Active Org.
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center [+29]
Originator Org.
Novartis Pharma AG
Active Indication
Conjunctivitis, Allergic [+38]
Inactive Indication
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia [+180]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date14 Nov 1983
12
Clinical Trials associated with Santen Pharmaceutical (China) Co. Ltd.
CTR20250080
/ CompletedPhase 1
一项在健康成人中进行的STN1013800滴眼液多次给药，药代动力学研究
[Translation] A multiple-dose pharmacokinetic study of STN1013800 eye drops in healthy adults
CTR20234212
/ CompletedPhase 3
0.1%STN1011403滴眼液治疗过敏性结膜炎的多中心随机评价者盲态阳性对照试验
[Translation] A multicenter randomized evaluator-blind positive controlled trial of 0.1% STN1011403 eye drops in the treatment of allergic conjunctivitis
CTR20230922
/ CompletedPhase 1
以健康中国成年人为对象评价STN1013400 滴眼液的安全性及药代动力学的临床试验
[Translation] A clinical trial evaluating the safety and pharmacokinetics of STN1013400 eye drops in healthy Chinese adults
100 Clinical Results associated with Santen Pharmaceutical (China) Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Santen Pharmaceutical (China) Co. Ltd.
Login to view more data
100 Deals associated with Santen Pharmaceutical (China) Co. Ltd.
Login to view more data
100 Translational Medicine associated with Santen Pharmaceutical (China) Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Tafluprost/Timolol Maleate
 ( PTGFR x β-adrenoceptors )		Ocular Hypertension
More
Approved
Cyclosporine
 ( CaN )		Conjunctivitis, Allergic
More
Approved
Sodium Hyaluronate
Corneal Injuries
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free